Partner Fund Management »

Inhibrx Biosciences shares owned by Partner Fund Management

Quarter-by-quarter ownership of Inhibrx Biosciences shares owned by Partner Fund Management from 13F filings

Historical chart of Partner Fund Management investment in Inhibrx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx Biosciences held by Partner Fund Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx Biosciences by Partner Fund Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $1.9M 136k 14.17

More positions owned by Partner Fund Management

Eli Lilly & Co. (LLY)
Cytokinetics Com New (CYTK)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Tenet Healthcare Corp Com New (THC)
Merck & Co (MRK)
Vertex Pharmaceuticals Incorporated (VRTX)
Abbvie (ABBV)
Edwards Lifesciences (EW)
UnitedHealth Call Option (UNH)
Intuitive Surgical Com New (ISRG)
McKesson Corporation (MCK)
Spdr Ser Tr S&p Biotech Call Option (XBI)
Humana (HUM)
Hca Holdings (HCA)
Centene Corporation (CNC)

View all positions for Partner Fund Management

Top funds holding Inhibrx Biosciences

Viking Global Investors
Perceptive Advisors
BlackRock
Vanguard Group
Sofinnova Ventures
Slotnik Capital
Alpine Associates Management
Millennium Management
TIG Advisors
Morgan Stanley
Ikarian Capital
Geode Capital Management
Caption Management
Marshall Wace
CSS

View all funds holding Inhibrx Biosciences